


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I:



wherein R_1 and R_2 are each independently H, or cyclopropyl alkyl, cycloalkyl, aryl, heteroaryl, $C(O)R_{7z}$, OR_{7z} or $C(O)NR_7R_8$, wherein the cyclopropyl alkyl, cycloalkyl, aryl and heteroaryl groups group may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, $-OH$, $-OR_{7z}$, a heteroalicyclic group, and a trihaloalkyl group;

~~R_3 and R_4 are each independently selected from the group consisting of H, halo, alkyl, aryl, heteroaryl, heteroalicyclic, $-OH$, $-OR_{7z}$, $-NR_7R_8$, $-(CH_2)_nC(O)OR_{7z}$, $-SO_2R_{7z}$, $-(CH_2)_nC(O)NR_7R_8$, $-C(S)NR_7R_8$, $-C(O)R_{7z}$, $-NR_7C(O)R_{8z}$, $-NHC(O)OR_{8z}$, $-NR_7C(O)NR_8R_9$, $-SO_2NR_7R_8$, $-OC(O)OR_{7z}$, $-OC(O)NR_7R_8$, $-CN$ and $-NO_2$, wherein the alkyl, aryl, heteroaryl and heteroalicyclic groups may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_{7z}$, $-NR_7R_8$, $-NR_7C(O)R_{8z}$, aryl, $-C(O)OR_{7z}$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_{7z}$, $-NR_7C(O)OR_{8z}$, $-SO_2R_{7z}$, $-NR_7C(O)NR_8R_9$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;~~

R_5 is phenyl selected from the group consisting of H, aryl, or halo, wherein the phenyl aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, ~~hydroxy or protected hydroxy~~, $-OR_{7z}$, $-NR_7R_8$, $-NR_7C(O)R_{8z}$, aryl, $-C(O)OR_{7z}$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_{7z}$, $-NR_7C(O)OR_{8z}$, $-SO_2R_{7z}$, $-NR_7C(O)NR_8R_9$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

wherein at least one of R_3 , R_4 and R_5 is an aryl;

R_6 is H;

R_7 , R_8 and R_9 are independently H, alkyl, aralkyl, heterocycloalkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, $-OH$, alkoxy, amino, $-NO_2$ and $-CN$;


alternatively, NR_7R_8 can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than 4 of the heteroatoms (N, O, or S), and the cyclic structure formed about NR_7R_8 may be substituted with

one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, heteroalicyclic, aryl, heteroaryl and halo; and

wherein n is 0, 1, 2 or 3; wherein one of R_1 or R_2 is cyclopropyl;
or a pharmaceutically acceptable salt thereof.

2. (Canceled)

3. (Withdrawn) A compound of formula I:



wherein R_1 and R_2 are each independently H, alkyl, cycloalkyl, aryl, heteroaryl, $-C(O)R_7$, $-OR_7$ or $-C(O)NR_7R_8$ wherein the alkyl, cycloalkyl, aryl and heteroaryl groups may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, $-OH$, $-OR_7$, a heteroalicyclic group, and a trihaloalkyl group;

R_3 is aryl, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_8R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

R_4 is H;

R_5 is selected from the group consisting of H, aryl or halo, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_8R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

R_6 is H;


R_7 , R_8 and R_9 are independently H, alkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, $-OH$, alkoxy, amino, $-NO_2$ and $-CN$;

alternatively, NR_7R_8 can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than four heteroatoms (N, O, or S), and the cyclic structure formed about NR_7R_8 may be substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, heteroalicyclic, aryl, heteroaryl and halo; and

wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

4. (Withdrawn) A compound of formula I:



wherein R_1 and R_2 are each independently H, alkyl, cycloalkyl, aryl, heteroaryl, $-C(O)R_7$, $-OR_7$ or $-C(O)NR_7R_8$ wherein the alkyl, cycloalkyl, aryl and heteroaryl groups may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, $-OH$, $-OR_7$, a heteroalicyclic group, and a trihaloalkyl group;

R_3 is H;

R_4 is aryl, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_8R_9$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

R_5 is selected from the group consisting of H, aryl or halo, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_8R_9$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

R_6 is H;

R_7 , R_8 and R_9 are independently H, alkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, hydroxy, alkoxy, amino, $-NO_2$ and $-CN$;

alternatively, NR_7R_8 can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than four heteroatoms (N, O, or S), and the cyclic structure formed about NR_7R_8 may be substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, hydroxy, heteroalicyclic, heterocycloalkyl, aryl, heteroaryl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl and halo; and

wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

5. (Withdrawn) The compound of claim 1, wherein R_4 and R_5 are optionally substituted aryl.

6. (Currently Amended) A compound selected from the group consisting of:

Methyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;

3-Phenyl-imidazo[1,2-a]pyrazin-8-ylamine;
 3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-ylamine;
 N-[4-(4-trifluoromethyl-benzamide-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-4-trifluoromethyl-benzamide;
 N-[4-(8-Amino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-4-trifluoromethyl-benzamide;
 (4-Methoxy-phenyl)-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol;
 Dimethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 Isopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 4-(8-Isopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol;
 Butyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 Ethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 (2-Morpholin-4-yl-ethyl)-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 Benzyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 2-(3-Phenyl-imidazo[1,2-a]pyrazin-8-ylamino)-ethanol;
 1-Butyl-3-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-urea;
 N-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide;
 N-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide;
 2,6-Dimethyl-4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol;
 3-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-ylamine;
 Cyclopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 [3-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 Methyl-[3-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 Methyl-[3-(3-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 Methyl-[3-(2-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 (3-Biphenyl-2-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine;
 [3-(2-Benzoyloxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone;
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone;
 [3-(3-Isopropyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 [3-(4-tert-Butyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 [3-(4-Cyclohexyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 [3-(3,5-Bis-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid;
 3-(8-Methylamino-imidazo[1,2-a]pyrazin-4-yl)-benzoic acid;
 Methyl-(3-o-tolyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 [4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid-benzyl-ester;

Methyl-[3-(4-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 [3-(2,4-Difluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 [3-(3,4-Dichloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 [3-(3-Fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 (3-Biphenyl-4-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine;
 (3-Biphenyl-3-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine;
 [3-(4-Benzoyloxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 Methyl-(3-naphthalen-1-yl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 [3-(2-Chloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 N-[3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]acetamide;
 Methyl-[3-(2-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 Methyl-[3-(3-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 Cyclopropyl-[3-(3-(2-morpholin-4-yl-ethoxy)-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol;
 Methyl-[3-(4-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 [3-(2-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 [3-(3,4-Difluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 (3-Benzo[1,3]dioxol-5-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine;
 [3-(3-Chloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 [3-(4-Methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 [3-(2-Methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 Methyl-[3-(4-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 [3-(4-Benzoyloxy-3-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 [3-(4-Isopropyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 [3-(3,5-Bis-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine;
 Cyclopropyl-[3-(3,4-dichloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid;
 Methyl-[3-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl]-amine;
 Cyclopropyl-[3-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl]-amine;
 Cyclopropyl-[3-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 Cyclopropyl-[3-(4-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone;
 [4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester;
 N-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide;
 [3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine;
 [3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 Methyl-(3-naphthalen-2-yl-imidazo[1,2-a]pyrazin-8-yl)-amine;

4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,
 [3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,
 Methyl-[3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl]-amine,
 [3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(2-morpholin-4-yl-ethyl)-benzamide,
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(3-morpholin-4-yl-propyl)-benzamide,
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(3-pyrrolidin-1-yl-propyl)-benzamide,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
 (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-
 imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 (S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-
 imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 (S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-
 a]pyrazin-3-yl)-phenyl]-amide,
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
 (S)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-
 yl)-phenyl]-amide,
 (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-
 a]pyrazin-3-yl)-phenyl]-amide,
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,
 4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-
 yl)-phenyl]-amide,
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,
 4-Hydroxy-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-
 phenyl]-amide,
 (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-
 a]pyrazin-3-yl)-phenyl]-amide,
 4-Hydroxy-piperidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-
 phenyl]-amide,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
 (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-
 a]pyrazin-3-yl)-phenyl]-amide,

(R)-2-Dimethylaminomethyl-pyrrolidine-1-carboxylic acid-[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide;
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea;
 (R)-3-Hydroxy-pyrrolidine-1-carboxylic acid-[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide;
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea;
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea;
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea;
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea;
 [5-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 Methyl-(5-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 Methyl-(5-thiophen-3-yl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-5-yl)-phenol;
 N-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-5-yl)-phenyl]-acetamide;
 [3,5-Bis-(4-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 (3,5-Diphenyl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine;
 Methyl-(6-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-6-yl)-phenol;
 6-Phenyl-imidazo[1,2-a]pyrazin-8-ylamine and
 Dimethyl-(3-phenyl-imidazo[1,2-a]pyrazin-5-yl)-amine;
 or a prodrug or pharmaceutically acceptable salt thereof.

7. (Currently Amended) A compound selected from the group consisting of:

Methyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol, —
 Ethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 Cyclopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine;
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone;
 [4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid-benzyl-ester;
 [3-(3-Fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;
 3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol;
 Methyl-[3-(4-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine;
 [3-(4-Benzyloxy-3-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine;

Cyclopropyl-[3-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,
 [4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,
 [3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,
 [3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 Methyl-(3-naphthalen-2-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,
 [3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,
 [3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
 (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-
 imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 (S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-
 imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 (S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-
 a]pyrazin-3-yl)-phenyl]-amide,
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
 (S)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-
 yl)-phenyl]-amide,
 (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-
 a]pyrazin-3-yl)-phenyl]-amide,
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,
 4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-
 yl)-phenyl]-amide,
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,
 4-Hydroxy-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-
 phenyl]-amide,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,
 (R)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-
 yl)-phenyl]-amide,
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-
 urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea and

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

or a ~~prodrug or~~ pharmaceutically acceptable salt thereof.

8. (Withdrawn) A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt of a compound of any one of claims 1, 2, 3, 4, 5 or 6 and pharmaceutically acceptable carrier or excipient.

9-16. (Canceled)